Informed Prostate Cancer Patient Support

The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016 | Prostate Cancer and Prostatic Diseases nature prostate cancer and prostatic diseases articles Published: 30 March 2024 The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016 Cooper Desmond , Sumedh Kaul , Aaron Fleishman , Ruslan Korets , Peter Chang , Andrew Wagner , Simon P. Kim , Nima Aghdam , Aria F. Olumi &  Boris Gershman   Prostate Cancer and Prostatic Diseases ( 2024 ) Cite this article Abstract Ba

Celebrities Handle Cancer Some Cancer Patients Can Find It Hard to Tell Family and Friends | MedPage Today medpagetoday.com Oncology/Hematology > Other Cancers — Recent high-profile examples highlight this reluctance by March 31, 2024 Ever since Anthony Bridges found out he had prostate cancer 6 years ago, he hasn't stopped talking about it. He told his Facebook friends immediately. Now, the 68-year-old man from Georgia spends time working with others to encourage other men to talk to their doctor about getting screened. Not everyone is as eager to share, for cultural or privacy reasons -- or because they just don't want to talk about it. Def

Graphical Abstract and Summary for Patients Here is a summary in layman's language: This study compared survival outcomes between two common prostate cancer drugs, abiraterone and enzalutamide, in elderly men with advanced prostate cancer who had not yet received chemotherapy. The researchers analyzed Medicare claims data from nearly 5,500 patients. The key findings were: Patients who received abiraterone had worse overall survival compared to those who received enzalutamide. The median survival was 20.6 months for abiraterone versus 22.5 months for enzalutamide. The reduced survival with abiraterone was particularly pronounced in certain patient subgroups, including those 75 years or older, white patients, those with cardiovascular disease, diabetes, or kidney disease, and patients across different socioeconomic levels. No subgroups were identified where abiraterone provided better survival than enzalutamide. The researchers concluded that in this Medicare population of